With over 500 lawyers we would expect to be able to provide the specialist skill and experience that you need. Browse our lawyers and teams below.
With nearly 500 lawyers we have the skills and experience you need.
Are you coming to one of our offices and need to know how to find us?
Send us your enquiry and we will get back to you as soon as possible
In a recent webinar, James Fry and Mark Davison of Mills & Reeve were joined by Josh Shin and Yongjin Zhu of Fangda Partners. This was a fascinating discussion of the issues non-Chinese licensors should consider when collaborating with local Chinese partners to exploit commercial opportunities in the Chinese market.
As the Chinese life sciences market continues to grow and develop, the Chinese government continues to de-regulate or streamline its regulatory pathways (such as its drug approval regimes). And as Chinese parties seek to exploit foreign technologies, there are increasing opportunities for overseas life sciences and biotechnology licensors to exploit market opportunities in PRC. However, PRC is a complex market. Its regulatory framework is different to that which many non-Chinese parties will be used to.
The panel sought to debunk some of the myths around commercialising opportunities in PRC. Six top key themes emerged that overseas licensors should consider before embarking in partnering with local Chinese parties:
You can access the webinar here using password: Life_sciences_March _2021.
For more information and to discuss any of the issues discussed, please get in touch.
Senior Legal Adviser
Register for My M&R to stay up-to-date with legal news and events, create brochures and bookmark pages.
Log in to your client extranet for free matter information, know-how and documents.
Mills & Reeve system for employees.
Added to your bookmarks
This will be stored in your bookmarks list for 90 days or until you remove it.
This page has been added to your brochure. To manage your brochure click on the button below.
Or click on
at the top of every page.